Skip to main content

 

The Center and its core facilities have been instrumental in developing public and private partnerships and have played a key role developing and submitting to federal agencies cross-disciplinary grant applications for research on nanomedicine technologies including successful renewal of the Carolina Center of Cancer Nanotechnology Excellence (CCNE) and establishment of the Carolina Cancer Nanotechnology Training Program (C-CNTP).

  1. Biomaterials to Study Tolerance Immune Induction Kinetics
    R01AI137525
    NIAID, 08/14/2018 – 07/31/2023; Role: PI
  2. Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
    R01AI141333
    NIAID, 12/14/2018 – 11/30/2023; Role: Co-Investigator
  3. Center for Influenza Vaccine Research in High Risk Populations
    SUB00002146-3A
    University of Georgia Research Foundation, 09/10/2019 – 09/09/2022; Role: PI
  4. Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
    R01AI147497
    NIAID, 01/15/2020 – 12/31/2024; Role: PI
  5. Formulation to Generate Tolerance Towards Type 1 Diabetes
    R01DK130225
    NIDDK, 07/01/2021 – 04/30/2025; Role: PI
  6. Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
    R01CA257009
    NCI, 08/01/2021 – 07/31/2026; Role: PI
  1. Biomaterials to Study Tolerance Immune Induction Kinetics
    R01AI137525
    NIAID, 08/14/2018 – 07/31/2023; Role: Co-Investigator
  2. Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
    R01AI141333
    NIAID, 12/14/2018 – 11/30/2023; Role: Co-PI
  3. Center for Influenza Vaccine Research in High Risk Populations
    SUB00002146-3A
    University of Georgia Research Foundation, 09/10/2019 – 09/09/2022; Role: Co-Investigator
  4. Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
    R01AI147497
    NIAID, 01/15/2020 – 12/31/2024; Role: Co-Investigator
  5. Formulation to Generate Tolerance Towards Type 1 Diabetes
    R01DK130225
    NIDDK, 07/01/2021 – 04/30/2025; Role: Co-Investigator
  6. Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
    R01CA257009
    NCI, 08/01/2021 – 07/31/2026; Role: Co-Investigator
  1. Cell-Based Platform for Gene Delivery to the Brain
    R01NS102412
    NINDS, 03/01/2018 – 11/30/2022; Role: PI
  2. Extracellular Vesicles for CNS Delivery of Therapeutic Enzymes to Treat Lysosomal Storage Disorders
    R01NS112019
    NINDS, 09/01/2019 – 06/30/2024; Role: PI
  3. A targeted anti-HIV drug delivery to the GALT
    R01AI147731
    NIAID, 07/16/2020 – 06/30/2025; Role: Co-Investigator
  1. Image-Guided, Ultrasound-Enhanced Long-Term Intracranial Drug Delivery
    R21CA246414
    NCI, 02/15/2020 – 01/31/2023; Role: Co-PI
  2. Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production
    R37CA260223
    NCI, 04/16/2021 – 03/31/2026; Role: PI
  1. Academic-Industrial Partnership for Translation of Acoustic Angiography
    R01CA189479
    NCI, 09/04/2014 – 08/31/2026; Role: PI
  2. High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging
    R01CA220681
    NCI, 09/04/2014 – 08/31/2026; Role: PI
  3. Treating Tumoral Hypoxia via Ultrasound-Guided Oxygen Release for Improving Radiation Therapy
    R01CA232148
    NCI, 06/01/2018 – 05/31/2024; Role PI
  4. Acoustic Angiography Using Dual-Frequency and Ultrawideband CMUT Arrays
    R01EB026897
    NIBIB, NC State University, 07/01/2018 – 03/31/2023; Role: Co-PI
  5. Next Generation Ultra-Long Acting Antiretroviral Formulations for HIV Treatment and Prevention
    R01AI140799
    NIAID, 09/24/2018 – 08/31/2023; Role: Co-Investigator
  6. Image-Guided, Ultrasound-Enhanced Long-Term Intracranial Drug Delivery
    R21CA246414
    NCI, 02/15/2020 – 01/31/2023; Role: Co-PI
  7. Parametric Optimization of Ultrasound-Mediated Immuno-Modulation for Pancreatic Cancer Therapy
    R21CA246550
    NCI, 04/01/2020 – 03/31/2023; Role: Co-PI
  8. Gas microbubbles as a hyperpolarized-xenon carrier and as a contrast agent for MRI
    R21EB031319
    NIBIB, 04/01/2021 – 01/31/2023; Role: Co-Investigator
  1. Selective Targeting Reactive Oxygen Species for Age-Related Macular Degeneration
    M2019063
    BrightFocus Foundation, 07/01/2019 – 06/30/2022; Role: PI
  1. Nanofiber Matrices to Improve Neural Stem Cell-Mediated Cancer Therapy
    R01NS097507
    NINDS, 06/01/2016 – 05/31/2021; Role: PI
  2. Engineering Stem Cell Therapies to Understand and Overcome Glioblastoma Adaption
    R01NS099368
    NINDS, 09/26/2017 – 06/30/2022; Role: PI
  3. Harnessing Synthetic Biology to Develop Next-Generation Cell Therapies
    Eshelman Institute for Innovation, 06/01/2019 – 05/31/2021; Role: PI
  1. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  2. Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  3. Inhibition of GTPases and G Proteins to Treat Human Disease
    R01GM120291
    NIGMS, 09/15/2016 – 07/31/2020; Role: Co-Investigator
  4. Discovery of In Vivo Chemical Probes for Polycomb CBX Domains
    R01CA218392
    NCI, 04/01/2018 – 03/31/2021; Role: Co-Investigator
  5. Targeting Tumor Associated Fibroblasts to Enhance Therapy
    Eshelman Institute for Innovation, 06/01/2019 – 05/31/2021; Role: PI
  1. Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
    R01CA184088
    NCI, 01/01/2015 – 12/31/2020; Role: PI
  2. Carolina Cancer Nanotechnology Training Program (C-CNTP)
    T32CA196589
    NCI, 07/01/2015 – 06/30/2025; Role: Director
  3. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    U01CA198910
    NCI, 08/14/2015- 07/31/2020; Role: PI
  4. Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  5. Targeted Magneto-Mechanic Nanotherapeutics for Cancer
    R21CA220148
    NCI, 08/1/2017 – 07/31/2020; Role: PI
  6. Nanoparticle Delivery of Cas9 and Therapeutic gRNAs to the Brain
    Eshelman Institute for Innovation, 06/01/2018 – 05/31/2020; Role: PI
  7. Targeting of Inflamed Monocytes for Gene Therapy of Cancer
    Eshelman Institute for Innovation, 06/01/2019 – 05/31/2020; Role: PI
  8. Targeting Tumor Associated Fibroblasts to Enhance Therapy
    Eshelman Institute for Innovation, 06/01/2019 – 05/31/2021; Role: Co-Investigator
  1. Overcoming anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
    R01HL141934
    NHLBI, 05/10/2018 – 04/30/2022; Role: PI
  2. In Vivo Engineering of T-cells for CAR-T-based Therapy
    Eshelman Institute for Innovation, 06/01/2018—05/31/2020; Role: PI
  3. SBIR: Development of a Biologic for Non-Hormonal Contraception
    R43HD094454
    NICHD, Mucommune, 07/08/2018 – 06/30/2020; Role: Co-Investigator
  4. Dynamic Tuning of Barrier Properties of Hydrogels Using Weakly Adhesive Third-Party Crosslinkers
    DMR-1810168
    NSF, 08/01/2018 – 07/31/2021; Role: PI
  5. STTR: An Integrated Neural Network Analysis and Video Microscopy Platform for Fully Automated Particle Tracking
    R41GM130202
    NIGMS, AI Tracking Solutions, 09/13/2018 – 09/12/2022; Role: PI
  6. SBIR: Capsule-Intravaginal Ring Providing Sustained Release of Antibodies for Non-Hormonal Contraception and Prevention of Vaginal HIV Transmission
    R44HD097063
    NICHD, Mucommune, 09/17/2018 – 08/31/2020; Role: Co-Investigator
  7. Protective Immune Mechanisms against Zika Virus Infection in the Female Reproductive Tract
    R21AI144631
    NIAID, 02/25/2019 – 01/31/2021; Role: Co-Investigator
  8. Engineering Edited B-cells for Long-Lasting and Potent Vaccination against HIV
    Eshelman Institute for Innovation, 06/01/2019—05/31/2021; Role: PI
  9. Engineering Bispecific Antibodies for Non-Hormonal Contraception
    R01HD101562
    NICHD, 04/01/2020 – 03/31/2024; Role: PI
  1. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    U01CA198910
    NCI, 08/14/2015 – 07/31/2020; Role: PI
  2. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  3. Inhibition Of GTPases and G Proteins to Treat Human Disease
    R01GM120291
    NIGMS, 09/15/2016 – 07/31/2020; Role: PI
  4. Nanoscintillator-Based X-ray Sensitizers to Enable Efficient Non-Small Cell Lung Cancer Treatment with X-ray Irradiation
    R01EB022596
    NIBIB, University of Georgia, 03/15/2017 – 01/31/2021; Role: Co-Investigator
  5. A Wholly Protein-Based Self-Assembly Nanoplatform for Tunable Cancer Immunotherapy
    Eshelman Institute for Innovation, 06/01/2018—05/31/2020; Role: PI
  1. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  2. HDAC11 Promotes Breast Cancer Metastasis via the Lymphatic Route
    Susan G. Komen for the Cure; 08/07/2017 – 08/06/2020; Role: PI
  3. Immune Regulation of Lung Squamous Metastasis
    R01CA215075
    NCI, 09/21/2017 – 08/31/2022; Role: PI
  4. Targeting GD2 Ganglioside in Small Cell Lung Cancer
    D2018-034
    V Foundation for Cancer Research, 09/15/2018 – 09/15/2021; Role: Co-Investigator
  1. Targeted Magneto-Mechanic Nanotherapeutics for Cancer
    R21CA220148
    NCI, 8/1/2017 – 7/31/2020; Role: Co-Investigator
  2. BCL-xL-regulated Apoptosis in Cerebellar Development and Medulloblastoma Treatment
    R01NS102627
    NINDS, 06/01/2018 – 04/30/2023; Role: Co-Investigator
  1. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  2. Integrating Cheminformatics and Molecular Simulations for Virtual Drug Screening
    R01GM114015
    NIGMS, 08/15/2016 – 05/31/2020; Role: Co-Investigator
  3. Drug Repurposing for Cancer Therapy: From Man to Molecules to Man
    U01CA207160
    NCI, 09/01/2016 – 08/31/2020; Role: PI
  4. Carolina Biomedical Data Translator Technical Feasibility Assessment and Architecture Design
    OT3TR002020
    NCATS, 09/24/2016 – 12/31/2020; Role: PI
  5. Chemoenzymatic Synthesis, Mode of Action and Evolution of Natural Product-Based Macrocycles
    R35GM125005
    NIGMS, 09/05/2017 – 08/31/2022; Role: Co-Investigator
  6. Carolina Biomedical Data Translator Technical Feasibility Assessment of Reasoning Tool
    OT2TR002514
    NCATS, 01/05/2018 – 12/31/2020; Role: PI
  7. Dual Mechanism Thiopeptide Analogs for TB Drug Development
    R21AI138058
    NIAID, 05/10/2018 – 04/30/2020; Role: Co-Investigator
  8. Drug Repurposing for Alzheimer’s Disease Using both Observational and Chemical Genomics Data
    R56AG059428
    NIA, 08/15/2018 – 07/31/2020; Role: PI
  9. Medical Learning Through Machine Learning (ML2)
    W81XWH18C0371
    DOD, 09/17/2018 – 09/09/2020; Role: PI
  1. Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
    UM1CA186704
    NCI, Duke University, 04/04/2014 – 02/28/2021; Role: Co-Investigator
  2. Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
    R01CA184088
    NCI, 01/01/2015 – 12/31/2020; Role: PI
  3. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    U01CA198910
    NCI, 08/14/2015 – 07/31/2020; Role: Co-Investigator
  4. Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  5. Overcoming Anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
    R01HL141934
    NHLBI, 05/10/2018 – 04/30/2022; Role: PI